Analyses of the PBI-05204–treated U87 cells revealed significant 73% declines in expression of Sox2 and a moderate reduction of other tumor stem cell markers CD44 and CXCR4 (Figure 4C). This evidence concerns the gene SOX2 and neoplasm.